Cargando…
Focal lung infiltrate complicating PD-1 inhibitor use: A new pattern of drug-associated lung toxicity?
A 58-year-old woman with stage 4 adenocarcinoma of the lung being treated with pembrolizumab developed dyspnea, non-productive cough, and a right middle lobe infiltrate. Complete resolution of the infiltrate with cessation of pembrolizumab, initiation of prednisone and no antibiotic therapy suggeste...
Autores principales: | Sehgal, Sameep, Velcheti, Vamsidhar, Mukhopadhyay, Sanjay, Stoller, James K. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5026692/ https://www.ncbi.nlm.nih.gov/pubmed/27668174 http://dx.doi.org/10.1016/j.rmcr.2016.09.001 |
Ejemplares similares
-
Role of immune-checkpoint inhibitors in lung cancer
por: Jain, Prantesh, et al.
Publicado: (2018) -
A Case of a Patient with Idiopathic Pulmonary Fibrosis with Lung Squamous Cell Carcinoma Treated with Nivolumab
por: Khunger, Monica, et al.
Publicado: (2017) -
Management of patients with advanced non-small cell lung cancer: role of gefitinib
por: Velcheti, Vamsidhar, et al.
Publicado: (2010) -
Real-world PD-L1 testing and distribution of PD-L1 tumor expression by immunohistochemistry assay type among patients with metastatic non-small cell lung cancer in the United States
por: Velcheti, Vamsidhar, et al.
Publicado: (2018) -
Clinical significance of PD-L1 protein expression on tumor-associated macrophages in lung cancer
por: Schalper, Kurt Alex, et al.
Publicado: (2015)